Insmed (INSM) EBIT (2010 - 2026)

Insmed's EBIT history runs 17 years deep, the most recent figure standing at -$153.3 million for Q1 2026.

• In Q1 2026, EBIT rose 38.21% year-over-year to -$153.3 million; the TTM figure through Mar 2026 stood at -$1.2 billion (down 17.44% YoY), while the FY2025 annual figure was -$1.2 billion, down 41.96% from the prior year.
• EBIT for Q1 2026 stood at -$153.3 million, up from -$319.7 million in the prior quarter.
• The five-year high for EBIT was -$88.3 million in Q2 2022, with the low at -$366.0 million in Q3 2025.
• The 5-year median for EBIT is -$178.3 million (2023), against an average of -$202.7 million.
• The sharpest annual moves came in 2023 and 2026: EBIT sank 166.69% in 2023, then surged 38.21% in 2026.
• Insmed's EBIT stood at -$151.5 million in 2022, then decreased by 17.69% to -$178.3 million in 2023, then decreased by 29.25% to -$230.4 million in 2024, then tumbled by 38.77% to -$319.7 million in 2025, then jumped by 52.05% to -$153.3 million in 2026.
• Business Quant data shows INSM's EBIT at -$153.3 million in Q1 2026, -$319.7 million in Q4 2025, and -$366.0 million in Q3 2025.